Literature DB >> 29468415

The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice.

Qiang Li1,2, Qiang Zhao1,2, Chuanzhao Zhang1,2, Peng Zhang1,2, Anbin Hu1,2, Longjuan Zhang3, Paul M Schroder4, Yi Ma1,2, Zhiyong Guo5,6, Xiaofeng Zhu7,8, Xiaoshun He9,10.   

Abstract

Fibroblast growth factor (FGF) has been considered to modulate liver regeneration (LR) after partial hepatectomy (PH) at the tissue level. Previous studies have demonstrated that FGF15 and FGF19 induce the activation of its receptor, FGF receptor 4 (FGFR4), which can promote hepatocellular carcinoma progression and regulate liver lipid metabolism. In this study, we aimed to explore the role of the ileal FGF15/19- hepatic FGFR4 axis in the LR after PH. Male C57BL/6 mice aged 8-12 weeks were partially hepatectomized and assessed for expression of ileal FGF15/19 to hepatic FGFR4 signaling. We used recombinant human FGF19 protein and a small interfering RNA (siRNA) of FGFR4 to regulate expression of the FGF15/19-FGFR4 axis in vitro and in vivo. The proliferation and cell cycle of hepatocytes, the expression levels of FGF15/19-FGFR4 downstream molecules, liver recovery, and lipid metabolism were assessed. We found that both ileal and serum FGF15 expression were upregulated and hepatic FGFR4 was activated after PH in mice. FGF15/19 promoted cell cycle progression, enhanced proliferation, and reduced hepatic lipid accumulation of hepatocytes both in vitro and in vivo. Furthermore, the proliferative effect and lipid regulatory properties of FGF15/19 were dependent on FGFR4 in hepatocytes. In addition, ileal FGF15/19-hepatic FGFR4 transduction during hepatocyte proliferation was regulated by extracellular regulated protein kinase (ERK) 1/2. In conclusion, the ileal FGF15/19 to hepatic FGFR4 axis is activated and promotes LR after PH in mice, supporting the potential of ileal FGF15/19 to hepatic FGFR4 axis-targeted therapy to enhance LR after PH.

Entities:  

Keywords:  FGF15; FGF19; FGFR4; Hepatectomy; Liver regeneration

Mesh:

Substances:

Year:  2018        PMID: 29468415     DOI: 10.1007/s13105-018-0610-8

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  51 in total

Review 1.  Transcription networks and cyclin/CDKs: the yin and yang of cell cycle oscillators.

Authors:  Laura A Simmons Kovacs; David A Orlando; Steven B Haase
Journal:  Cell Cycle       Date:  2008-09-26       Impact factor: 4.534

2.  Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4.

Authors:  C Yu; F Wang; M Kan; C Jin; R B Jones; M Weinstein; C X Deng; W L McKeehan
Journal:  J Biol Chem       Date:  2000-05-19       Impact factor: 5.157

Review 3.  The mechanisms of action of PPARs.

Authors:  Joel Berger; David E Moller
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

4.  Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice.

Authors:  Lisheng Zhang; Yan-Dong Wang; Wei-Dong Chen; Xichun Wang; Guiyu Lou; Nian Liu; Min Lin; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

5.  Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration.

Authors:  Gloria Alvarez-Sola; Iker Uriarte; M Ujue Latasa; Maite G Fernandez-Barrena; Raquel Urtasun; Maria Elizalde; Marina Barcena-Varela; Maddalen Jiménez; Haisul C Chang; Roberto Barbero; Victoria Catalán; Amaia Rodríguez; Gema Frühbeck; José M Gallego-Escuredo; Aleix Gavaldà-Navarro; Francesc Villarroya; Carlos M Rodriguez-Ortigosa; Fernando J Corrales; Jesus Prieto; Pedro Berraondo; Carmen Berasain; Matias A Avila
Journal:  Gut       Date:  2017-01-24       Impact factor: 23.059

6.  FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action.

Authors:  Dong-Ju Shin; Timothy F Osborne
Journal:  J Biol Chem       Date:  2009-02-23       Impact factor: 5.157

7.  Impaired liver regeneration in mice by lipopolysaccharide via TNF-alpha/kallikrein-mediated activation of latent TGF-beta.

Authors:  Kuniharu Akita; Masataka Okuno; Masamichi Enya; Shoko Imai; Hisataka Moriwaki; Norifumi Kawada; Yasuhiro Suzuki; Soichi Kojima
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

8.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Authors:  Ling Fu; Linu M John; Sean H Adams; Xing Xian Yu; Elizabeth Tomlinson; Mark Renz; P Mickey Williams; Robert Soriano; Racquel Corpuz; Barbara Moffat; Richard Vandlen; Laura Simmons; Jessica Foster; Jean-Philippe Stephan; Siao Ping Tsai; Timothy A Stewart
Journal:  Endocrinology       Date:  2004-02-19       Impact factor: 4.736

9.  Functional Relationships between Lipid Metabolism and Liver Regeneration.

Authors:  David A Rudnick; Nicholas O Davidson
Journal:  Int J Hepatol       Date:  2012-01-26

10.  Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system.

Authors:  Maria U Latasa; Fabiana Salis; Raquel Urtasun; Oihane Garcia-Irigoyen; Maria Elizalde; Iker Uriarte; Monica Santamaria; Francesco Feo; Rosa M Pascale; Jesús Prieto; Carmen Berasain; Matías A Avila
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  4 in total

1.  Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.

Authors:  Yuan Tian; Jingwei Cai; Wei Gui; Robert G Nichols; Imhoi Koo; Jingtao Zhang; Mallappa Anitha; Andrew D Patterson
Journal:  Drug Metab Dispos       Date:  2018-11-08       Impact factor: 3.922

2.  Transcriptional trajectories of human kidney injury progression.

Authors:  Pietro E Cippà; Bo Sun; Jing Liu; Liang Chen; Maarten Naesens; Andrew P McMahon
Journal:  JCI Insight       Date:  2018-11-15

Review 3.  The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.

Authors:  Lulu Sun; Jie Cai; Frank J Gonzalez
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-02-10       Impact factor: 46.802

Review 4.  FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.

Authors:  Emma Henriksson; Birgitte Andersen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-22       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.